# Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

> **NCT00131144** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 583 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Octreotide Acetate in Microspheres 20 mg
- **DRUG:** Octreotide Acetate in Microspheres
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00131144
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 583 (ACTUAL)
- **Last updated:** 2011-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131144, "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00131144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*